Navigation Links
Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease
Date:6/9/2008

- Data from Pivotal Study Highlighted at Recent Arizona Alzheimer's

Consortium Annual Conference in Phoenix -

PHOENIX and SUN CITY, Ariz., June 9 /PRNewswire/ -- Banner Alzheimer's Institute and Sun Health Research Institute today announced that they are actively enrolling patients in a new study of the investigational drug Dimebon(TM) for the treatment of Alzheimer's disease. The study will evaluate the safety and efficacy of Dimebon in patients with Alzheimer's disease taken in combination with Aricept(R) (donepezil HCI tablets), an FDA-approved Alzheimer's treatment.

According to new estimates from the Alzheimer's Association, more than 5 million people in the United States are living with Alzheimer's disease, a progressive, debilitating and deadly neurodegenerative disease that destroys brain cells and affects areas of the brain involved in memory, cognition, judgment, language and behavior. Currently available therapies for Alzheimer's treat the symptoms with modest effect in most patients; new therapies are urgently needed.

Results from a one-year study of Dimebon in mild-to-moderate Alzheimer's disease -- showing statistically significant improvements in memory, thinking, function and behavior -- were highlighted at the recent 2008 Arizona Alzheimer's Consortium (AAC) Annual Conference, a community service event. Banner Alzheimer's Institute and Sun Health Research Institute are both members of the Consortium.

"We are encouraged by the results Dimebon has shown in clinical studies to date and believe it is imperative to fully assess its promise in the fight against Alzheimer's disease," said Pierre N. Tariot, M.D., director, Memory Disorders Center, Banner Alzheimer's Institute. "We are pleased to be participating in this study."

"As the baby boomer population ages, the incidence of Alzheimer's will dramatically increase. We must find innovative ways to treat this devastating disease and slow its progression," said Marwan Sabbagh, M.D., founder and director of clinical research at Sun Health Research Institute's Cleo Roberts Center for Clinical Research. "We encourage local patients and caregivers to learn more about possible enrollment in this study, as clinical research is vitally important to understanding how we can better treat Alzheimer's disease."

About the Study

The multi-phase 1/2 study is designed to evaluate the safety, tolerability and pharmacokinetics(1) of the investigational drug Dimebon in the treatment of patients with Alzheimer's disease. Patients aged 50 and older with a clinical diagnosis of Alzheimer's disease, taking Aricept for at least 60 days prior to enrollment, may be eligible to participate in the study. The trial is sponsored by Medivation, Inc.

For more information about the study, please contact:

-- Banner Alzheimer's Institute, (602) 239-6900

-- Sun Health Research Institute, (623) 875-6500 or visit

http://www.shri.org (for information on all clinical trials)

About Dimebon

Dimebon is an investigational therapy in clinical development for the treatment of Alzheimer's disease. It targets Alzheimer's disease differently than currently available therapies. Initial studies of Dimebon have shown promise and further study is indicated.

About Banner Alzheimer's Institute

Banner Alzheimer's Institute is a treatment and research facility dedicated to helping patients with memory and thinking problems. It offers clinical care for patients; provides education, referral and support services for family and caregivers; and conducts leading-edge research in clinical trials, brain imaging and genetics studies. The Institute is devoted to finding effective Alzheimer's disease-slowing and prevention treatments in the shortest time possible. Banner Alzheimer's Institute is owned and operated by Phoenix-based Banner Health, a nonprofit organization.

About Sun Health Research Institute

For 21 years, Sun Health Research Institute has been a leader nationally and internationally in the effort to find answers to disorders of aging including Alzheimer's disease, Parkinson's disease, arthritis and prostate cancer. The institute, together with its Arizona Alzheimer's Consortium partners, has been designated by the National Institutes of Health as one of just 31 Alzheimer's Disease Centers in the nation. The institute's Cleo Roberts Center for Clinical Research takes laboratory discoveries to clinical trials that foster hope for new treatments. Sun Health Research Institute is affiliated with the Sun Health non-profit community healthcare network.

(1) Pharmacokinetics is the process by which a drug is absorbed,

distributed, metabolized and eliminated by the body.


'/>"/>
SOURCE Banner Alzheimer's Institute; Sun Health ResearchInstitute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Karmanos Cancer Institute Researchers Show Phase I Immunotherapy with Armed T Cells Improve Overall Survival of Metastatic Breast Cancer Patients
2. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
3. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
4. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
5. Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women
6. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
7. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
8. Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease
9. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
10. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
11. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: ... that developed an innovative way to use nonlinear optical ... delivery of new drugs. ... Dermatology Conference will show how researchers from BioPharmX and ... Medical School used a suite of imaging techniques in ...
(Date:10/11/2017)... 11, 2017  True Health, a leader in ... effort during National Breast Cancer Awareness month to ... Research recently ... that more than 10 million American women are ... BRCA1 or BRCA2 and have not had testing. These ...
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance in ... medical-grade battery-powered display stand specifically designed for endoscopy environments. An innovative ... into a clinical solution to support the improvement of patient outcomes, ... Design ... Solution ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is ... vendors and unique items from across the nation, this holiday-themed event will raise funds ... by the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... ... ... Planet Fitness, one of the largest and fastest growing franchisors and operators ... location in Covington, LA at 401 N. U.S. Highway 190, in January of 2018. ... in the Holiday Square shopping center. Its location allows it to serve both Covington ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based ... and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored ... 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, ...
Breaking Medicine News(10 mins):